行情

ABIO

ABIO

方舟生物医药
NASDAQ

实时行情|Nasdaq Last Sale

2.880
+0.120
+4.35%
交易中 15:52 04/08 EDT
开盘
2.900
昨收
2.760
最高
2.900
最低
2.761
成交量
7,629
成交额
--
52周最高
20.45
52周最低
2.210
市值
459.09万
市盈率(TTM)
-0.6370
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ABIO价格均价为7.00,最高价位7.00,最低价为7.00。

EPS

ABIO 新闻

更多
  • The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
  • Benzinga · 03/13 11:52
  • The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
  • Benzinga · 02/28 12:28
  • WLL, SPEX, CODX and AIM among midday movers
  • Seeking Alpha - Article · 02/27 18:00
  • The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
  • Benzinga · 02/21 12:46

所属板块

制药
+3.50%
制药与医学研究
+3.45%

热门股票

代码
价格
涨跌幅

ABIO 简况

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
展开

微牛提供Arca Biopharma Inc(NASDAQ-ABIO)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ABIO股票新闻,以帮助您做出投资决策。